This morning shares of CytoDyn Inc. (OTMKTS: CYDY) screamed higher in very active trading and touched $7.00 per share to a $4.14 billion market...
Only Mesoblast (NASDAQ:MESO) and CytoDyn Inc. (OTCMKS: CYDY) had mortality as a primary endpoint in severe to critical COVID-19.
100% correlation between this list and an EUA approval5 drug candidates on the list have not received an EUA3 drug candidates seem imminent What this...
In the interim, no patients can get the drug via emergency IND because the FDA has stopped that access. This is a point of moral outrage. By not looking at the interim data for leronlimab in an urgent fashion the FDA is condemning thousands of people to death daily.
First Graphene, in a partnership with newGen Group, forwarded graphene solutions to Rio Tinto (ASX: RIO) and BHP Group (ASX: BHP)
Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.
FingerMotion could be on an exponential growth trajectory and the stock price along with it. Their large inflow of capital should be responsible for another strong performance in the current quarter. AliBaba’s (NASDAQ: BABA) singles day (November 11th) is in the current quarter.
After the initial deadly volley from the novel coronavirus, the broader healthcare industry’s attention shifted from developing treatments to researching and developing vaccines. Not...
The recent pandemic brought with it both a collapse in energy prices and stock markets, followed by a massive run-up in stocks to which big oil majors like Lukoil (OTCMKTS: LUKOY), Gazprom (OTCMKTS: OGZPY), Total S.A. (NYSE: TOT), Exxon (NYSE: XOM), BP plc (NYSE: BP), Chevron (NYSE: CVX), and Phillips 66 (NYSE: PSX) have only marginally benefited from. With the energy shakeout continuing, unexpected new winners have emerged servicing regional niche markets who are poised to make serious cash flow.
Galectin Therapeutics Inc. (NASDAQ: GALT) shot up close to 32.4% on Monday on record breaking volume of 4.9 million shares in anticipation of a long awaited investor conference call at 4PM ET on September 29th. In after hours trading the stock continues to climb to $4.20. GALT has one of the worst track records when it comes to shareholder communications with only 9 press releases this year, so it's easy to see why shareholders might be excited and speculating on news during the conference. GALT’s long term holders have pointed to outgoing CEO Harold Shlevin for the lack of communication while he focused on finishing the NASH phase 3 clinical trial design which took close to 2 years to complete.